Ruxolitinib mesilate
Added to RFQ
For Research & Analytical Purposes. Not for Personal use.
Packaging & Handling
Indicative product packaging is shown for visual reference. Actual packaging may vary based on pack size, quantity, storage condition and shipping requirements.
Documentation Available
Detailed specifications, certificates, and supporting documents are available upon request.
Detailed specifications, certificates, and supporting documents are available upon request.
Storage: Refer MSDS for complete information.
Hazard: Refer MSDS for complete information.
Ruxolitinib mesilate Product Information
Ruxolitinib mesilate is listed under Impurity and is intended for analytical research, quality control and pharmaceutical reference standard applications. It is associated with Ruxolitinib. The product is supplied by Clearsynth under CAT No. CS-O-64521.
Clearsynth provides this compound for research and analytical use, with product information including CAS number, molecular formula, molecular weight and product enquiry details.
Technical Data
Product Name
Ruxolitinib mesilate
CAS No.
2927441-77-6
CAT No.
CS-O-64521
HSN Code
38229010
Country of Origin
Can be shipped from India, Canada and USA
Molecular Formula
C18H22N6O3S
Molecular Weight
402.47
Category
API Family
Storage Condition
Refer MSDS for complete information.
Hazard Compound
Refer MSDS for complete information.
Description
Regulatory Description
Ruxolitinib mesilate is supplied with detailed characterization data compliant with regulatory guideline. Ruxolitinib mesilate can be used for analytical method development, method validation (AMV), Quality Control (QC) application for Abbreviated New Drug Application (ANDA), or during commercial production of Ruxolitinib.
Overview
Useful research chemical for a range of applications.
Synonyms
Ruxolitinib mesilate
Application Notes
Useful research chemical for a range of applications.
Product Applications & Regulatory Search Terms
Useful product, supplier and regulatory search terms for this reference standard.